Engineered and fully-functional customized glycoproteins
AssigneeLimmatech Biologics AG
InventorsAmirreza Faridmoayer, Manuela Mally, Rainer Follador
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.
Claims64
A Leishmania host cell comprising:
- a. a recombinant nucleic acid encoding a target protein;
- and
- b. a recombinant nucleic acid encoding a heterologous glycosyltransferase.
47-55. (canceled)
61-77. (canceled)
A hybrid N-acetyl glucosamine transferase, wherein the hybrid N-acetyl glucosamine transferase comprises
- c. catalytic domain of an N-acetyl glucosamine transferase that is not from Leishmania;
- and
- d. amino acid sequence(s) responsible for localization and retention in the endoplasmic reticulum or Golgi compartment of Leishmania.
79-84. (canceled)
A hybrid galactosyltransferase, wherein the hybrid galactosyltransferase comprises
- e. catalytic domain of a galactosyltransferase that is not from Leishmania;
- and
- f. amino acid sequence(s) responsible for localization and retention in the endoplasmic reticulum or Golgi compartment of Leishmania.
86-94. (canceled)
A hybrid sialyltransferase, wherein the hybrid sialyltransferase comprises
- g. catalytic domain of a sialyltransferase that is not from Leishmania;
- and
- h. amino acid sequence(s) responsible for localization and retention in the endoplasmic reticulum or Golgi compartment of Leishmania.
96-101. (canceled)
103-107. (canceled)
Dependencies are inferred from the claim text.